Most important contact allergens in hand eczema.

[Most important contact allergens in hand eczema]. Hautarzt. 2019 Sep 10;: Authors: Mahler V, Dickel H Abstract The head and hands are the two most common locations for allergic contact dermatitis manifestation. In hand eczema, contact with a contact allergen is a frequent (co-)factor in the triggering and maintenance of eczema. For all hand eczemas lasting longer than 3 months, an allergological examination by means of patch testing is recommended. In patients with allergic contact dermatitis of the hands, nickel, MCI/MI, fragrance mix I, cobalt, thiuram mix, Balsam of Peru, chromium and fragrance mix II have been described in a multicenter European study as the most common contact allergens of the standard series. In the information network of dermatological clinics (IVDK) a total of 56,170 patients were patch-tested in the years 2014 to 2018. In all, 16,807 of these patients (29.9%) suffered from hand eczema, of which 7725 (46.0%) had occupational dermatosis (OD) and 6820 (40.6%) had no OD. For the remaining patients this was unknown. The top 30-list of allergens in hand eczema patients without and with OD included 22 common contact allergens, but with different reaction frequency. In hand eczema patients without OD, the following contact allergens also belong to this list: octyl gallate, sorbic acid, tert-butylhydroquinone, propylene glycol, mercury (II) amide chloride, tolubalsam, jasmine absolute, and san...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research

Related Links:

CONCLUSIONS: In adolescents with moderate-to-severe AD, dupilumab's pharmacokinetic profile was similar to that in adults. These 52-week safety and efficacy data support long-term use of dupilumab in this patient population. What's already known about this topic? Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet medical need, with significant disease burden and limited treatment options. Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candida...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conclusion: The study results validate that the botanical combination is the key factor for the efficacy and improvement of the AD symptoms within this population of children. J Drugs Dermatol. 2019;18(10):1038-1045. PMID: 31584783 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Conditions:   Atopic Dermatitis;   Atopic Eczema Interventions:   Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo;   Drug: Protopic, tacrolimus ointment 0.1% Sponsors:   Jacob Thyssen;   LEO Pharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
LOS ANGELES, Oct. 3, 2019 -- (Healthcare Sales &Marketing Network) -- Turn Therapeutics™, Inc., a Los Angeles-based pharmaceutical and medical device company, has announced the closing of its fully-subscribed series B financing. The capital raised will f... Biopharmaceuticals, Dermatology, Venture Capital Turn Therapeutics, AtopX, Eczema Emulsion, PermaFusion
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
CBS News Miami anchor Frances Wang, 27, was diagnosed this year with perioral dermatitis, a skin condition that occurs due to prolonged use of topical steroid creams for her eczema.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
ConclusionIn early infancy, distinct parental and pregnancy-related factors were predictive for dry skin, high TEWL and AD. Dry skin at 3 months of age was predictive for AD three months later.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Condition:   Atopic Dermatitis Eczema Intervention:   Other: Ectoin Dermatitis Cream 7% (EHK02) Sponsor:   Bitop AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Accidents | Allergy & Immunology | Chloride | Chromium | Cobalt | Dermatitis | Dermatology | Eczema | Insurance | Occupational Health | Peru Health | Skin | Study